Chemogenetic and pharmacological activation of the oxytocin system ameliorates adjuvant arthritis in rats
- 1Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health
- 2Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health
- 3Department of Physiology, School of Medicine, University of Occupational and Environmental Health
Abstract
Oxytocin (OXT) is an endogenous neuropeptide involved in the regulation of nociceptive processing and inflammatory responses. Chronic inflammatory arthritis is characterized by persistent inflammation and pain, and understanding neuroendocrine mechanisms that regulate both processes may provide new insights into the pathophysiology of chronic inflammatory pain. Previous studies have shown that endogenous OXT has both anti-inflammatory and antinociceptive effects, suggesting that activation of the OXT system may influence arthritis by modulating inflammatory and pain-related pathways. However, whether activation of endogenous OXT signaling can modulate the progression of chronic inflammatory arthritis and its associated pain remains incompletely understood. Therefore, this study investigated whether chemogenetic activation of OXT neurons and pharmacological stimulation of OXT receptors modulate disease progression and pain-related outcomes in a rat model of adjuvant arthritis. Adjuvant arthritis was induced in adult male OXT-hM3Dq-mCherry transgenic rats (n = 39) and adult male Wistar rats (n = 10). The transgenic rats were treated with CNO, whereas Wistar rats were treated with LIT-001, with the corresponding vehicle-treated groups serving as controls. Arthritis severity, ankle swelling, mechanical hypersensitivity, joint histopathology, and neuronal activity markers were evaluated. Chemogenetic activation of OXT neurons attenuated arthritis progression during both the onset phase (Days 10-12) and established phase (Days 15-17). During the onset phase, it also reduced ankle swelling and prevented the decline in mechanical nociceptive thresholds. Descriptive histological evaluation showed less pronounced inflammatory cell infiltration, synovial hyperplasia, pannus formation, cartilage destruction, and bone erosion in affected joints. Similarly, repeated administration of the oxytocin receptor agonist LIT-001 ameliorated arthritis severity, joint swelling, and inflammatory pain-related behaviors. Immunohistochemical analyses further revealed increased FosB expression in the paraventricular nucleus and reduced numbers of FosB-immunoreactive and tryptophan hydroxylase (TPH)-immunoreactive cells in the dorsal raphe nucleus following LIT-001 treatment. These findings show that chemogenetic activation of endogenous OXT neurons and administration of the OXT receptor agonist LIT-001 ameliorate arthritis pathology and inflammatory pain-related behaviors in adjuvant arthritis. The OXT system may therefore contribute to the regulation of chronic inflammatory arthritis through coordinated effects on peripheral inflammation and central pain processing.
Related
- Pharmacological Activation of Autophagy Ameliorates Neuromuscular-Associated Defects and Extends Lifespan in a Caenorhabditis elegans Model of Spinal Muscular Atrophy.
- Xinfeng capsule regulates pyroptosis and ameliorates cardiac fibrosis in rheumatoid arthritis through lncRNA GAS5 and TLR4/ROS/miR-21 pathways
- Sanguinarine ameliorates rheumatoid arthritis by activating the Hippo-YAP/TAZ pathway to induce apoptosis and suppress inflammation in fibroblast-like synoviocytes
- Nebivolol ameliorates CFA-induced adjuvant arthritis and is associated with reduced WNT5A and active β-catenin protein levels
- Pharmacological Antagonism of HTR2B Reduces ERK and STAT3 Activation and Prevents Renal Fibrosis During the Development of Adenine-Induced CKD in Rats
BibTeX
@article{hashimoto2026chemogenetic,
title = {{Chemogenetic and pharmacological activation of the oxytocin system ameliorates adjuvant arthritis in rats}},
author = {Wataru Hashimoto and Hitoshi Suzuki and Hiroaki Fujihara and Hiromichi Ueno and Hajime Fukushima and Rie Ariyoshi and Manabu Tsukamoto and Makoto Kawasaki and Tomoya Arashi and Takafumi Horishita and Akinori Sakai and Yoichi Ueta and Takashi Maruyama},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1941424},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1941424/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Chemogenetic and pharmacological activation of the oxytocin system ameliorates adjuvant arthritis in rats
AU - Wataru Hashimoto
AU - Hitoshi Suzuki
AU - Hiroaki Fujihara
AU - Hiromichi Ueno
AU - Hajime Fukushima
AU - Rie Ariyoshi
AU - Manabu Tsukamoto
AU - Makoto Kawasaki
AU - Tomoya Arashi
AU - Takafumi Horishita
AU - Akinori Sakai
AU - Yoichi Ueta
AU - Takashi Maruyama
PY - 2026
DA - 2026/10/30
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1941424
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1941424/full
AB - Oxytocin (OXT) is an endogenous neuropeptide involved in the regulation of nociceptive processing and inflammatory responses. Chronic inflammatory arthritis is characterized by persistent inflammation and pain, and understanding neuroendocrine mechanisms that regulate both processes may provide new insights into the pathophysiology of chronic inflammatory pain. Previous studies have shown that endogenous OXT has both anti-inflammatory and antinociceptive effects, suggesting that activation of the OXT system may influence arthritis by modulating inflammatory and pain-related pathways. However, whether activation of endogenous OXT signaling can modulate the progression of chronic inflammatory arthritis and its associated pain remains incompletely understood. Therefore, this study investigated whether chemogenetic activation of OXT neurons and pharmacological stimulation of OXT receptors modulate disease progression and pain-related outcomes in a rat model of adjuvant arthritis. Adjuvant arthritis was induced in adult male OXT-hM3Dq-mCherry transgenic rats (n = 39) and adult male Wistar rats (n = 10). The transgenic rats were treated with CNO, whereas Wistar rats were treated with LIT-001, with the corresponding vehicle-treated groups serving as controls. Arthritis severity, ankle swelling, mechanical hypersensitivity, joint histopathology, and neuronal activity markers were evaluated. Chemogenetic activation of OXT neurons attenuated arthritis progression during both the onset phase (Days 10-12) and established phase (Days 15-17). During the onset phase, it also reduced ankle swelling and prevented the decline in mechanical nociceptive thresholds. Descriptive histological evaluation showed less pronounced inflammatory cell infiltration, synovial hyperplasia, pannus formation, cartilage destruction, and bone erosion in affected joints. Similarly, repeated administration of the oxytocin receptor agonist LIT-001 ameliorated arthritis severity, joint swelling, and inflammatory pain-related behaviors. Immunohistochemical analyses further revealed increased FosB expression in the paraventricular nucleus and reduced numbers of FosB-immunoreactive and tryptophan hydroxylase (TPH)-immunoreactive cells in the dorsal raphe nucleus following LIT-001 treatment. These findings show that chemogenetic activation of endogenous OXT neurons and administration of the OXT receptor agonist LIT-001 ameliorate arthritis pathology and inflammatory pain-related behaviors in adjuvant arthritis. The OXT system may therefore contribute to the regulation of chronic inflammatory arthritis through coordinated effects on peripheral inflammation and central pain processing.
SN - 1664-2392
ER -